MX379318B - Metodos para tratar trastornos de sueño de ritmo circadiano. - Google Patents

Metodos para tratar trastornos de sueño de ritmo circadiano.

Info

Publication number
MX379318B
MX379318B MX2018013663A MX2018013663A MX379318B MX 379318 B MX379318 B MX 379318B MX 2018013663 A MX2018013663 A MX 2018013663A MX 2018013663 A MX2018013663 A MX 2018013663A MX 379318 B MX379318 B MX 379318B
Authority
MX
Mexico
Prior art keywords
methods
sleep disorders
circadian rhythm
rhythm sleep
treating circadian
Prior art date
Application number
MX2018013663A
Other languages
English (en)
Spanish (es)
Other versions
MX2018013663A (es
Inventor
Andrew Satlin
Carsten T Beuckmann
Margaret Moline
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MX2018013663A publication Critical patent/MX2018013663A/es
Publication of MX379318B publication Critical patent/MX379318B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2018013663A 2016-05-12 2017-05-11 Metodos para tratar trastornos de sueño de ritmo circadiano. MX379318B (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662335611P 2016-05-12 2016-05-12
US201662335599P 2016-05-12 2016-05-12
US201662413976P 2016-10-27 2016-10-27
US201662414599P 2016-10-28 2016-10-28
US201662414606P 2016-10-28 2016-10-28
PCT/US2017/032228 WO2017197160A1 (en) 2016-05-12 2017-05-11 Methods of treating circadian rhythm sleep disorders

Publications (2)

Publication Number Publication Date
MX2018013663A MX2018013663A (es) 2019-07-18
MX379318B true MX379318B (es) 2025-03-10

Family

ID=58745465

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018013663A MX379318B (es) 2016-05-12 2017-05-11 Metodos para tratar trastornos de sueño de ritmo circadiano.

Country Status (16)

Country Link
US (2) US11096941B2 (enExample)
EP (2) EP3454859B1 (enExample)
JP (2) JP6888026B2 (enExample)
KR (2) KR20230043227A (enExample)
CN (1) CN109640998A (enExample)
AU (3) AU2017264871B2 (enExample)
CA (1) CA3022068A1 (enExample)
ES (1) ES2904625T3 (enExample)
IL (2) IL291791B2 (enExample)
MX (1) MX379318B (enExample)
MY (1) MY199382A (enExample)
RU (1) RU2763493C2 (enExample)
SG (1) SG11201809527UA (enExample)
TW (1) TWI795359B (enExample)
WO (1) WO2017197160A1 (enExample)
ZA (1) ZA201807903B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2763493C2 (ru) * 2016-05-12 2021-12-29 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Способы лечения расстройств циркадного ритма сна
JP2022538170A (ja) * 2019-06-26 2022-08-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 睡眠問題の治療のためのレンボレキサント
WO2020263253A1 (en) * 2019-06-26 2020-12-30 Moline Margaret Lemborexant for treating sleep issues
CA3144067A1 (en) * 2019-06-26 2020-12-30 Eisai R&D Management Co., Ltd. Lemborexant for treating sleep issues
CA3151634A1 (en) * 2019-09-13 2021-03-18 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating insomnia
EP4073058A1 (en) * 2019-12-11 2022-10-19 Teva Czech Industries s.r.o. Solid state form of lemborexant
MX2022008260A (es) * 2020-01-16 2022-08-04 Eisai R&D Man Co Ltd Sustancia farmacologica de lemborexant y composicion medicinal que la comprende.
CN111450076A (zh) * 2020-05-25 2020-07-28 安徽省逸欣铭医药科技有限公司 一种Lemborexant软胶囊组合物及其制备方法
CN114159568B (zh) * 2020-09-11 2025-08-01 北京原基华毅生物科技有限公司 Sik抑制剂在制备用于预防和/或治疗睡眠障碍的药物中的应用
EP4376954A1 (en) * 2021-07-26 2024-06-05 Eisai R&D Management Co., Ltd. Lemborexant for use in methods of treating irregular sleep-wake rhythm disorder and circadian rhythm sleep disorders associated with neurodegenerative diseases
CN116421605B (zh) * 2022-01-04 2024-08-02 中国科学院脑科学与智能技术卓越创新中心 Isx-9在治疗衰老相关的昼夜节律幅度下降和睡眠障碍方面的应用
CA3266968A1 (en) 2022-09-23 2024-03-28 Eisai R&D Management Co., Ltd. Methods of reducing neurodegeneration associated with neurodegenerative diseases
CN121646412A (zh) 2023-08-08 2026-03-10 株式会社明治 昼夜节律的调整

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2556753C (en) * 2004-02-20 2014-11-25 Lifescape Biosciences Incorporated Compositions and methods for sleep regulation
WO2008026149A1 (en) * 2006-08-28 2008-03-06 Actelion Pharmaceuticals Ltd 1,4,5,6, 7,8-hexahydro-i^1s-triaza-azulene derivatives as orexin receptor antagonists
MY160969A (en) 2010-09-22 2017-03-31 Eisai R&D Man Co Ltd Cyclopropane compounds
RU2014136339A (ru) * 2012-02-07 2016-03-27 Иолас Терапьютикс, Инк. Замещенные пролины/пиперидины как антагонисты орексиновых рецепторов
MX376164B (es) * 2014-10-23 2025-03-07 Eisai R&D Man Co Ltd Composiciones y metodos para tratar el insomnio.
RU2763493C2 (ru) * 2016-05-12 2021-12-29 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Способы лечения расстройств циркадного ритма сна

Also Published As

Publication number Publication date
EP3454859A1 (en) 2019-03-20
KR20190013820A (ko) 2019-02-11
MX2018013663A (es) 2019-07-18
ZA201807903B (en) 2021-04-28
CA3022068A1 (en) 2017-11-16
EP3454859B1 (en) 2021-12-01
TWI795359B (zh) 2023-03-11
US20210353625A1 (en) 2021-11-18
MY199382A (en) 2023-10-25
US20200179382A1 (en) 2020-06-11
KR20230043227A (ko) 2023-03-30
TW201740952A (zh) 2017-12-01
IL262803A (en) 2018-12-31
IL291791A (en) 2022-06-01
NZ748555A (en) 2025-06-27
RU2018143809A3 (enExample) 2020-09-17
RU2018143809A (ru) 2020-06-15
JP2021120410A (ja) 2021-08-19
AU2017264871B2 (en) 2023-03-16
IL262803B (en) 2022-05-01
KR102511855B1 (ko) 2023-03-20
AU2017264871A1 (en) 2018-11-15
IL291791B1 (en) 2025-05-01
WO2017197160A1 (en) 2017-11-16
ES2904625T3 (es) 2022-04-05
US11096941B2 (en) 2021-08-24
IL291791B2 (en) 2025-09-01
BR112018073037A2 (pt) 2019-02-26
JP7150096B2 (ja) 2022-10-07
SG11201809527UA (en) 2018-11-29
EP4056180A1 (en) 2022-09-14
JP2019518732A (ja) 2019-07-04
AU2025205336A1 (en) 2025-07-31
JP6888026B2 (ja) 2021-06-16
CN109640998A (zh) 2019-04-16
AU2023203418A1 (en) 2023-06-29
RU2763493C2 (ru) 2021-12-29

Similar Documents

Publication Publication Date Title
MX379318B (es) Metodos para tratar trastornos de sueño de ritmo circadiano.
PH12019501575A1 (en) ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFá1 INHIBITORS AND USE THEREOF
PH12016501809A1 (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
JO3553B1 (ar) تعديل المناعة ضد الورم
UY35464A (es) Inhibidores covalentes de kras g12c.
EA201790737A1 (ru) Комбинированная терапия
EA201790195A1 (ru) Способы лечения рака с применением ингибиторов tigit и противораковых агентов
MX2023000796A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
HUE061761T2 (hu) Tetrahidropiranil-amino-pirrolopirimidinon felhasználásra BTK-által közvetített zavarok kezelésében
BR112018001853A2 (pt) métodos para tratamento de um distúrbio e para melhoria do tratamento de um distúrbio
EA201692477A1 (ru) Композиции и способы применения для лечения метаболических расстройств
BR112017018964A2 (pt) uso de plinabulin e métodos para tratar tumor cerebral
BR112017005598A2 (pt) macrociclos peptidomiméticos e usos dos mesmos
MX385425B (es) Irinotecán liposomal y oxaliplatino, 5-fluoroacilo y leucovorina para usarse en el tratamiento de cáncer pancreático metastásico.
HUE060496T2 (hu) Terápiás vegyületek és készítmények szociális zavarok és szerhasználati zavarok kezelésére
DK3442513T3 (da) Anvendelse af cannabidiolsyre i behandling af autismespektrumforstyrrelse og forbundne forstyrrelser
CO2020001107A2 (es) Moduladores terapéuticos del modo inverso de la atp sintasa
CY1125113T1 (el) Συνθεσεις και μεθοδοι για χρηση στην αγωγη της ομοκυστινουριας
BR112016015997A2 (pt) ?composições farmacêuticas que compreendem 15- hepe e métodos para tratar asma e distúrbios pulmonares com o uso das mesmas?
IL253582B (en) Detection and treatment of malignant tumours in the cns
EP3402468C0 (en) PI3K P-DELTA 110 INHIBITORS FOR USE IN DELIVERY OF VIRUSES TO TREAT CANCER
MX2018002298A (es) Metodos de uso de interleucina 10 para el tratamiento de enfermedades y trastornos.
PL3630112T3 (pl) Kombinacja regorafenibu i niwolumabu w leczeniu nowotworu
HUE054910T2 (hu) Indazole vegyületek ín és/vagy ínszalag sérülés kezelésében történõ alkalmazásra
MX2019003314A (es) Metodos de tratamiento de la elevacion de dominio 3 de inmunoglobulina de celula t y mucina (tim-3).